Taysha Gene Therapies (TSHA) Tops Q2 EPS by 7c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q2 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.11 million versus the consensus estimate of $2.76 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• DEFSEC Technologies (DFSC) files for 4.05M share offering by selling stockholders
• White House: barrels from Venezuela deal could hit reserves in U.S. In November